2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis
Use of procalcitonin in neonatal late-onset sepsis may reduce the duration of antibiotic therapy without increase in mortality
Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes
Pharma 2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis June 3, 2026
Emergency Use of procalcitonin in neonatal late-onset sepsis may reduce the duration of antibiotic therapy without increase in mortality May 28, 2026
Chronic Disease Immunosuppression with systemic glucocorticoids close to initiation of immune checkpoint inhibitor is associated with worse survival outcomes May 25, 2026
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](data:image/svg+xml;base64,PHN2ZyB2aWV3Qm94PSIwIDAgMSAxIiB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==)
